Long-term administration of desferrioxamine in thalassaemia major.
D000293:Adolescent; D000328:Adult; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D001797:Blood Protein Electrophoresis; D001803:Blood Transfusion; D006332:Cardiomegaly / Q000150:complications; D002648:Child; D003676:Deferoxamine / Q000008:administration & dosage* / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006333:Heart Failure / Q000150:complications; D006486:Hemosiderosis / Q000188:drug therapy; D006529:Hepatomegaly / Q000150:complications; D006801:Humans; D007136:Immunoglobulins / Q000032:analysis; D007273:Injections, Intramuscular; D007501:Iron / Q000652:urine; D008111:Liver Function Tests; D008297:Male; D010493:Pericarditis / Q000150:complications; D013789:Thalassemia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000628:therapy / Q000652:urine; D013997:Time Factors
D007136:Immunoglobulins; D007501:Iron; D001219:Aspartate Aminotransferases; D003676:Deferoxamine; D001663:Bilirubin